The EGFR mutation rate in NSCLC is relatively high (~50.2%) and thus the EGFR-TKIs are the most commonly used targeted drugs for the treatment of NSCLC (6, 7). This evidence concerns the gene EGFR and non-small cell lung carcinoma.